Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | WDR5 | P61964 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.61 |
| ▸ | NPY1R | P25929 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
| ▸ | FASN | P49327 | 2/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rabeprazole SCHEMBL29360086 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL30945135 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL29374701 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL29833678 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL23337 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL29493315 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL30019061 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL23336 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL5945508 | 0.99 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL491362 | 0.99 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578742-B1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | NYCOMED GMBH (DE) | 2012-10-17 | — | — | EP | claimed |
| US-7452998-B2 | Process for preparing optically pure active compounds | NYCOMED GMBH (DE) | 2008-11-18 | — | — | US | claimed |
| US-20050288334-A1 | Process for preparing optically pure active compounds | ALTANA PHARMA AG (DE) | 2005-12-29 | — | — | US | claimed |
| EP-1578742-A1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | ALTANA Pharma AG (DE) | 2005-09-28 | — | — | EP | claimed |
| WO-2004052882-A1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-06-24 | — | — | WO | claimed |
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11078184-B2 | Dexrabeprazole sodium compound and pharmaceutical composition thereof | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200216414-A1 | DEXRABEPRAZOLE SODIUM COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| US-8420822-B2 | Optical resolution of substituted 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles | HETERO RESEARCH FOUNDATION (IN) | 2013-04-16 | — | — | US | disclosed |
| US-8420822-B2 | Optical resolution of substituted 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles | HETERO RESEARCH FOUNDATION (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-1578742-B1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | NYCOMED GMBH (DE) | 2012-10-17 | — | — | EP | disclosed |
| US-20090110727-A1 | Extended release compositions of proton pump inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20080275089-A1 | Compositions and methods to treat gastrointestinal disorders | EISAI CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080234325-A1 | Novel Methods Using Pyridine Derivatives | EISAI CO., LTD. | 2008-09-25 | — | — | US | disclosed |
| US-20080234325-A1 | Novel Methods Using Pyridine Derivatives | EISAI CO., LTD. | 2008-09-25 | — | — | US | disclosed |
| US-20080090877-A1 | Salts Of Benzimidazole Derivative With Amines And Process For Manufacturing The Same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090877-A1 | Salts Of Benzimidazole Derivative With Amines And Process For Manufacturing The Same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1775292-A1 | SALTS OF BENZIMIDAZOLE DERIVATIVE WITH AMINES AND PROCESS FOR PRODUCTION THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20070060622-A1 | Compositions and methods using proton pump inhibitors | EISAI CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216414-A1 | DEXRABEPRAZOLE SODIUM COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | CYP2C19, CYP2B6, CYP2D6 | KMT2A 4196/4885CYP2C9 17/4885WDR5 3606/4885 |
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | KMT2A 3380/4885CYP2C9 4152/4885WDR5 3395/4885 |
| US-20080234325-A1 | Novel Methods Using Pyridine Derivatives | IL33, GPR34, IL23R | KMT2A 4327/4885CYP2C9 728/4885WDR5 1581/4885 |
| US-20080090877-A1 | Salts Of Benzimidazole Derivative With Amines And Process For Manufacturing The Same | EIF3I, GIPR, AZI2 | KMT2A 2244/4885CYP2C9 204/4885WDR5 3187/4885 |
| US-11078184-B2 | Dexrabeprazole sodium compound and pharmaceutical composition thereof | CYP2C19, CYP2B6, CYP2D6 | KMT2A 4196/4885CYP2C9 17/4885WDR5 3606/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | KMT2A 3380/4885CYP2C9 4152/4885WDR5 3395/4885 |
| US-20090110727-A1 | Extended release compositions of proton pump inhibitors | GIPR, GRPR, HRH2 | KMT2A 3646/4885CYP2C9 279/4885WDR5 1262/4885 |
| US-20070060622-A1 | Compositions and methods using proton pump inhibitors | CFTR, ATP6V1G1, P2RX3 | KMT2A 3784/4885CYP2C9 886/4885WDR5 4025/4885 |
| US-20080275089-A1 | Compositions and methods to treat gastrointestinal disorders | RAB39A, RAB1A, RAB7A | KMT2A 1298/4885CYP2C9 1602/4885WDR5 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.